Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis

April W. Armstrong, Keith A. Betts, Murali Sundaram, Darren Thomason, James E. Signorovitch

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: To our knowledge, no clinical trials directly compare apremilast with methotrexate (the standard of care for initial systemic treatment of psoriasis). Objective: We sought to compare apremilast's relative efficacy with that of methotrexate for moderate to severe psoriasis. Methods: An anchor-based indirect comparison was conducted for 75% improvement in Psoriasis Area and Severity Index score from baseline to week 16 (PASI 75) rates for systemic-naïve patients from Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis (ESTEEM) 1 and 2 (apremilast vs placebo) and Comparative study of HumirA vs. Methotrexate vs Placebo In psOriasis patieNts (CHAMPION) (adalimumab vs methotrexate vs placebo) trials. The difference-in-difference in PASI 75 response rates was calculated as the difference between the ESTEEM apremilast and placebo rates and the CHAMPION methotrexate versus placebo rates. Number needed to treat and incremental drug cost per responder were also estimated. Results: No statistically significant difference was found between apremilast and methotrexate in PASI 75 (risk difference 13.1%; 95% confidence interval -1.8% to 28.0%; . P = .09). Number needed to treat with apremilast versus methotrexate to gain 1 additional PASI 75 responder was 7.6. Annual incremental drug cost of this responder was estimated at $187,888.33. Limitations: Few trials compare systemic-naïve patients. Only direct medication costs were considered. Conclusions: There was no statistical evidence of greater efficacy for apremilast versus methotrexate. The $187,888 incremental cost per PASI 75 may exceed what payers are willing to pay.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
DOIs
StateAccepted/In press - 2016
Externally publishedYes

Fingerprint

Psoriasis
Methotrexate
Costs and Cost Analysis
Placebos
Numbers Needed To Treat
Drug Costs
apremilast
Standard of Care
Patient Safety
Clinical Trials
Confidence Intervals
Safety

Keywords

  • Apremilast
  • Cost per responder
  • Cost-effectiveness
  • Indirect comparison
  • Methotrexate
  • Moderate to severe psoriasis
  • Number needed to treat
  • Psoriasis Area and Severity Index

ASJC Scopus subject areas

  • Dermatology

Cite this

Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. / Armstrong, April W.; Betts, Keith A.; Sundaram, Murali; Thomason, Darren; Signorovitch, James E.

In: Journal of the American Academy of Dermatology, 2016.

Research output: Contribution to journalArticle

@article{e00d7458ddca4680928a30f1702f954e,
title = "Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-na{\"i}ve patients with psoriasis",
abstract = "Background: To our knowledge, no clinical trials directly compare apremilast with methotrexate (the standard of care for initial systemic treatment of psoriasis). Objective: We sought to compare apremilast's relative efficacy with that of methotrexate for moderate to severe psoriasis. Methods: An anchor-based indirect comparison was conducted for 75{\%} improvement in Psoriasis Area and Severity Index score from baseline to week 16 (PASI 75) rates for systemic-na{\"i}ve patients from Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis (ESTEEM) 1 and 2 (apremilast vs placebo) and Comparative study of HumirA vs. Methotrexate vs Placebo In psOriasis patieNts (CHAMPION) (adalimumab vs methotrexate vs placebo) trials. The difference-in-difference in PASI 75 response rates was calculated as the difference between the ESTEEM apremilast and placebo rates and the CHAMPION methotrexate versus placebo rates. Number needed to treat and incremental drug cost per responder were also estimated. Results: No statistically significant difference was found between apremilast and methotrexate in PASI 75 (risk difference 13.1{\%}; 95{\%} confidence interval -1.8{\%} to 28.0{\%}; . P = .09). Number needed to treat with apremilast versus methotrexate to gain 1 additional PASI 75 responder was 7.6. Annual incremental drug cost of this responder was estimated at $187,888.33. Limitations: Few trials compare systemic-na{\"i}ve patients. Only direct medication costs were considered. Conclusions: There was no statistical evidence of greater efficacy for apremilast versus methotrexate. The $187,888 incremental cost per PASI 75 may exceed what payers are willing to pay.",
keywords = "Apremilast, Cost per responder, Cost-effectiveness, Indirect comparison, Methotrexate, Moderate to severe psoriasis, Number needed to treat, Psoriasis Area and Severity Index",
author = "Armstrong, {April W.} and Betts, {Keith A.} and Murali Sundaram and Darren Thomason and Signorovitch, {James E.}",
year = "2016",
doi = "10.1016/j.jaad.2016.05.040",
language = "English (US)",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis

AU - Armstrong, April W.

AU - Betts, Keith A.

AU - Sundaram, Murali

AU - Thomason, Darren

AU - Signorovitch, James E.

PY - 2016

Y1 - 2016

N2 - Background: To our knowledge, no clinical trials directly compare apremilast with methotrexate (the standard of care for initial systemic treatment of psoriasis). Objective: We sought to compare apremilast's relative efficacy with that of methotrexate for moderate to severe psoriasis. Methods: An anchor-based indirect comparison was conducted for 75% improvement in Psoriasis Area and Severity Index score from baseline to week 16 (PASI 75) rates for systemic-naïve patients from Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis (ESTEEM) 1 and 2 (apremilast vs placebo) and Comparative study of HumirA vs. Methotrexate vs Placebo In psOriasis patieNts (CHAMPION) (adalimumab vs methotrexate vs placebo) trials. The difference-in-difference in PASI 75 response rates was calculated as the difference between the ESTEEM apremilast and placebo rates and the CHAMPION methotrexate versus placebo rates. Number needed to treat and incremental drug cost per responder were also estimated. Results: No statistically significant difference was found between apremilast and methotrexate in PASI 75 (risk difference 13.1%; 95% confidence interval -1.8% to 28.0%; . P = .09). Number needed to treat with apremilast versus methotrexate to gain 1 additional PASI 75 responder was 7.6. Annual incremental drug cost of this responder was estimated at $187,888.33. Limitations: Few trials compare systemic-naïve patients. Only direct medication costs were considered. Conclusions: There was no statistical evidence of greater efficacy for apremilast versus methotrexate. The $187,888 incremental cost per PASI 75 may exceed what payers are willing to pay.

AB - Background: To our knowledge, no clinical trials directly compare apremilast with methotrexate (the standard of care for initial systemic treatment of psoriasis). Objective: We sought to compare apremilast's relative efficacy with that of methotrexate for moderate to severe psoriasis. Methods: An anchor-based indirect comparison was conducted for 75% improvement in Psoriasis Area and Severity Index score from baseline to week 16 (PASI 75) rates for systemic-naïve patients from Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis (ESTEEM) 1 and 2 (apremilast vs placebo) and Comparative study of HumirA vs. Methotrexate vs Placebo In psOriasis patieNts (CHAMPION) (adalimumab vs methotrexate vs placebo) trials. The difference-in-difference in PASI 75 response rates was calculated as the difference between the ESTEEM apremilast and placebo rates and the CHAMPION methotrexate versus placebo rates. Number needed to treat and incremental drug cost per responder were also estimated. Results: No statistically significant difference was found between apremilast and methotrexate in PASI 75 (risk difference 13.1%; 95% confidence interval -1.8% to 28.0%; . P = .09). Number needed to treat with apremilast versus methotrexate to gain 1 additional PASI 75 responder was 7.6. Annual incremental drug cost of this responder was estimated at $187,888.33. Limitations: Few trials compare systemic-naïve patients. Only direct medication costs were considered. Conclusions: There was no statistical evidence of greater efficacy for apremilast versus methotrexate. The $187,888 incremental cost per PASI 75 may exceed what payers are willing to pay.

KW - Apremilast

KW - Cost per responder

KW - Cost-effectiveness

KW - Indirect comparison

KW - Methotrexate

KW - Moderate to severe psoriasis

KW - Number needed to treat

KW - Psoriasis Area and Severity Index

UR - http://www.scopus.com/inward/record.url?scp=84979790339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979790339&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2016.05.040

DO - 10.1016/j.jaad.2016.05.040

M3 - Article

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

ER -